[1] Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer[J]. Nat Rev Cancer, 2011, 11(1): 9-22. [2] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002 [J]. CA Cancer J Clin, 2005, 55(2): 74-108. [3] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines?): Head and Neck Cancers (Version 2.2014) [DB/OL]. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. [4] Ma J, Liu Y, Huang XL, et al. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis[J]. Oral Oncol,2012,48(11): 1076-1084. [5] Zhong LP, Zhang CP, Ren GX, et al. Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6): 744-751. [6] Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology [J]. J Natl Cancer Inst, 1993, 85(5): 365-376. [7] Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-HN35) in head and neck patients: EORTC Quality of Life Group [J]. Eur J Cancer, 2000, 36(14): 1796-1807. [8] Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual [M]. 2nd Ed. Brussels: European Organization for Research and Treatment of Cancer, 1999. [9] Machin D, Weeden S. Suggestions for the presentation of quality of life data from clinical trials[J]. Stat Med,1998,17(5-7):711-724. [10] Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores [J]. J Clin Oncol, 1998, 16(1): 139-144. [11] Abdel-Wahab M, Abitbol A, Lewin A, et al. Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma [J]. Am J Clin Oncol, 2005, 28(4): 359-366. [12] van Herpen CM, Mauer ME, Mesia R, et al. EORTC head and neck group short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323) [J]. Br J Cancer, 2010, 103(8): 1173-1181. |